• 1
    Anderson CR, Hu X, Zhang H et al. Ultrasound molecular imaging of tumor angiogenesis with an integrin targeted microbubble contrast agent. Invest Radiol 2011; 46: 21524.
  • 2
    Beer AJ, Kessler H, Wester HJ, Schwaiger M. PET imaging of integrin alphaVbeta3 expression. Theranostics 2011; 1: 4857.
  • 3
    Pool SE, Krenning EP, Koning GA et al. Preclinical and clinical studies of peptide receptor radionuclide therapy. Semin Nucl Med 2010; 40: 20918.
  • 4
    Schnell O, Krebs B, Carlsen J et al. Imaging of integrin alpha(v)beta(3) expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography. Neuro Oncol 2009; 11: 86170.
  • 5
    Boturyn D, Coll JL, Garanger E, Favrot MC, Dumy P. Template assembled cyclopeptides as multimeric system for integrin targeting and endocytosis. J Am Chem Soc 2004; 126: 57309.
  • 6
    Garanger E, Boturyn D, Jin Z, Dumy P, Favrot MC, Coll JL. New multifunctional molecular conjugate vector for targeting, imaging, and therapy of tumors. Mol Ther 2005; 12: 116875.
  • 7
    Ahmadi M, Sancey L, Briat A et al. Chemical and biological evaluations of an (111)in-labeled RGD-peptide targeting integrin alpha(V) beta(3) in a preclinical tumor model. Cancer Biother Radiopharm 2008; 23: 691700.
  • 8
    Dimastromatteo J, Riou LM, Ahmadi M et al. In vivo molecular imaging of myocardial angiogenesis using the alpha(v)beta3 integrin-targeted tracer 99mTc-RAFT-RGD. J Nucl Cardiol 2010; 17: 43543.
  • 9
    Jin ZH, Furukawa T, Galibert M et al. Noninvasive visualization and quantification of tumor alphaVbeta3 integrin expression using a novel positron emission tomography probe, 64Cu-cyclam-RAFT-c(-RGDfK-)4. Nucl Med Biol 2011; 38: 52940.
  • 10
    Sancey L, Ardisson V, Riou LM et al. In vivo imaging of tumour angiogenesis in mice with the alpha(v)beta (3) integrin-targeted tracer 99mTc-RAFT-RGD. Eur J Nucl Med Mol Imaging 2007; 34: 203747.
  • 11
    Garanger E, Boturyn D, Dumy P. Tumor targeting with RGD peptide ligands-design of new molecular conjugates for imaging and therapy of cancers. Anticancer Agents Med Chem 2007; 7: 5528.
  • 12
    Jin ZH, Josserand V, Foillard S et al. In vivo optical imaging of integrin alphaV-beta3 in mice using multivalent or monovalent cRGD targeting vectors. Mol Cancer 2007; 6: 41.
  • 13
    Jin ZH, Josserand V, Razkin J et al. Noninvasive optical imaging of ovarian metastases using Cy5-labeled RAFT-c(-RGDfK-)4. Mol Imaging 2006; 5: 18897.
  • 14
    Dijkgraaf I, Kruijtzer JA, Liu S et al. Improved targeting of the alpha(v)beta (3) integrin by multimerisation of RGD peptides. Eur J Nucl Med Mol Imaging 2007; 34: 26773.
  • 15
    Rolleman EJ, Valkema R, de Jong M, Kooij PP, Krenning EP. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging 2003; 30: 915.
  • 16
    Christensen EI, Birn H. Megalin and cubilin: synergistic endocytic receptors in renal proximal tubule. Am J Physiol Renal Physiol 2001; 280: F56273.
  • 17
    Baines RJ, Brunskill NJ. The molecular interactions between filtered proteins and proximal tubular cells in proteinuria. Nephron Exp Nephrol 2008; 110: e6771.
  • 18
    Christensen EI, Verroust PJ. Megalin and cubilin, role in proximal tubule function and during development. Pediatr Nephrol 2002; 17: 9939.
  • 19
    ten Dam MA, Branten AJ, Klasen IS, Wetzels JF. The gelatin-derived plasma substitute Gelofusine causes low-molecular-weight proteinuria by decreasing tubular protein reabsorption. J Crit Care 2001; 16: 11520.
  • 20
    Veldman BA, Schepkens HL, Vervoort G, Klasen I, Wetzels JF. Low concentrations of intravenous polygelines promote low-molecular weight proteinuria. Eur J Clin Invest 2003; 33: 9628.
  • 21
    van Eerd JE, Vegt E, Wetzels JF et al. Gelatin-based plasma expander effectively reduces renal uptake of 111In-octreotide in mice and rats. J Nucl Med 2006; 47: 52833.
  • 22
    Foillard S, Sancey L, Coll JL, Boturyn D, Dumy P. Targeted delivery of activatable fluorescent pro-apoptotic peptide into live cells. Org Biomol Chem 2009; 7: 2214.
  • 23
    Keramidas M, Josserand V, Righini CA, Wenk C, Faure C, Coll JL. Intraoperative near-infrared image-guided surgery for peritoneal carcinomatosis in a preclinical experimental model. Br J Surg 2010; 97: 73743.
  • 24
    Dufort S, Sancey L, Hurbin A et al. Targeted delivery of a proapoptotic peptide to tumors in vivo. J Drug Target 2011; 19: 5828.
  • 25
    Melis M, Bijster M, de Visser M et al. Dose-response effect of Gelofusine on renal uptake and retention of radiolabelled octreotate in rats with CA20948 tumours. Eur J Nucl Med Mol Imaging 2009; 36: 196876.
  • 26
    Rolleman EJ, Melis M, Valkema R, Boerman OC, Krenning EP, de Jong M. Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues. Eur J Nucl Med Mol Imaging 2010; 37: 101831.
  • 27
    Vegt E, Eek A, Oyen WJ, de Jong M, Gotthardt M, Boerman OC. Albumin-derived peptides efficiently reduce renal uptake of radiolabelled peptides. Eur J Nucl Med Mol Imaging 2010; 37: 22634.
  • 28
    Valkema R, Pauwels SA, Kvols LK et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med 2005; 46(Suppl 1): 83S91S.
  • 29
    Vegt E, Wetzels JF, Russel FG et al. Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin. J Nucl Med 2006; 47: 4326.
  • 30
    Rolleman EJ, Bernard BF, Breeman WA et al. Molecular imaging of reduced renal uptake of radiolabelled [DOTA0,Tyr3]octreotate by the combination of lysine and Gelofusine in rats. Nuklearmedizin 2008; 47: 1105.
  • 31
    Gotthardt M, van Eerd-Vismale J, Oyen WJ et al. Indication for different mechanisms of kidney uptake of radiolabeled peptides. J Nucl Med 2007; 48: 596601.
  • 32
    Josserand V, Texier-Nogues I, Huber P, Favrot MC, Coll JL. Non-invasive in vivo optical imaging of the lacZ and luc gene expression in mice. Gene Ther 2007; 14: 158793.
  • 33
    Ring J, Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet 1977; 1: 4669.
  • 34
    Rolleman EJ, Krenning EP, Van Gameren A, Bernard BF, De Jong M. Uptake of [111In-DTPA0]octreotide in the rat kidney is inhibited by colchicine and not by fructose. J Nucl Med 2004; 45: 70913.
  • 35
    Galibert M, Sancey L, Renaudet O, Coll JL, Dumy P, Boturyn D. Application of click-click chemistry to the synthesis of new multivalent RGD conjugates. Org Biomol Chem 2010; 8: 51338.
  • 36
    Vegt E, de Jong M, Wetzels JF et al. Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med 2010; 51: 104958.
  • 37
    Stewart FA, Lebesque JV, Hart AA. Progressive development of radiation damage in mouse kidneys and the consequences for reirradiation tolerance. Int J Radiat Biol Relat Stud Phys Chem Med 1988; 53: 40515.
  • 38
    Bodei L, Cremonesi M, Ferrari M et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging 2008; 35: 184756.